Novartis, Aduro Launch Up-to-$750M Cancer Immunotherapy Collaboration

March 30, 2015 1:15 PM

19 0

Aduro Biotech launched a collaboration with Novartis to research, develop, and commercialize new immuno-oncology products, under a partnership that could generate up to $750 million for Aduro.

The companies committed themselves to developing new cancer immunotherapies based on Aduro’s cyclic dinucleotides (CDNs), synthetic small molecule immune modulators that are designed to target and activate the Stimulator of Interferon Genes (STING) receptor.

Read more

To category page